Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C Turner

Showing results (61-70 of 138) with videos related to

Pageof 14
Sort By:
Cancer Discovery|September 13, 2018
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 TrialBen O'Leary, Rosalind J Cutts, Yuan Liu, et al.
Nature Communications|March 3, 2018
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancerBen O'Leary, Sarah Hrebien, James P Morden, et al.
Plos One|September 29, 2015
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR ApproachAlexandra Pender, Isaac Garcia-Murillas, Sareena Rana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2010
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancerMonika Graeser, Afshan McCarthy, Christopher J Lord, et al.
Cancer Research|August 17, 2006
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibitionNuala McCabe, Nicholas C Turner, Christopher J Lord, et al.
Plos One|April 10, 2009
Integrated functional, gene expression and genomic analysis for the identification of cancer targetsElizabeth Iorns, Christopher J Lord, Anita Grigoriadis, et al.
EMBO Molecular Medicine|March 20, 2026
ctDNA monitoring using tumor-informed copy number analysisZe Zhou, Ros Cutts, Sarah Hrebien, et al.
British Journal of Cancer|May 21, 2021
Impact of timing of adjuvant chemothapy for early breast cancer: the Royal Marsden Hospital experienceAlicia F C Okines, Emma Kipps, Tazia Irfan, et al.
The Oncologist|July 3, 2016
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2018
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3Massimo Cristofanilli, Angela DeMichele, Carla Giorgetti, et al.
Pageof 14

Showing results (61-70 of 138) with videos related to

Sort By:
Pageof 14
Cancer Discovery|September 13, 2018
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 TrialBen O'Leary, Rosalind J Cutts, Yuan Liu, et al.
Nature Communications|March 3, 2018
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancerBen O'Leary, Sarah Hrebien, James P Morden, et al.
Plos One|September 29, 2015
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR ApproachAlexandra Pender, Isaac Garcia-Murillas, Sareena Rana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2010
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancerMonika Graeser, Afshan McCarthy, Christopher J Lord, et al.
Cancer Research|August 17, 2006
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibitionNuala McCabe, Nicholas C Turner, Christopher J Lord, et al.
Plos One|April 10, 2009
Integrated functional, gene expression and genomic analysis for the identification of cancer targetsElizabeth Iorns, Christopher J Lord, Anita Grigoriadis, et al.
EMBO Molecular Medicine|March 20, 2026
ctDNA monitoring using tumor-informed copy number analysisZe Zhou, Ros Cutts, Sarah Hrebien, et al.
British Journal of Cancer|May 21, 2021
Impact of timing of adjuvant chemothapy for early breast cancer: the Royal Marsden Hospital experienceAlicia F C Okines, Emma Kipps, Tazia Irfan, et al.
The Oncologist|July 3, 2016
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2018
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3Massimo Cristofanilli, Angela DeMichele, Carla Giorgetti, et al.
Pageof 14